Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Thenorth1990on Sep 02, 2021 3:25pm
180 Views
Post# 33804351

RE:Are we too late on our Covid serology test?

RE:Are we too late on our Covid serology test? We are not left with any choice when the last update we had about this after the Jv was about an appointment to commercialize, when they said expecting revenues by q3 2020. Now they have mentioned the new traget date is q4 2021. Also they did say they are limiting announcements to approval/revenue in that case if the current test listed by immusafe is accredited by college of physicians then they should let us know. We might not be late in terms of science, bt in terms of marketing this thing atleast to retail Investors we are light years late. Thanks to guys from Boston, I am least bothered about serology test. Next pr about serology might have another spike to 30cents and we will back to 20 cents. Hope I am wrong and hope we get govt /,pharma contracts
<< Previous
Bullboard Posts
Next >>